Hvilken er prisen på Harpoon Therapeutics, Inc. (HARP)

Prisen på Harpoon Therapeutics, Inc. (HARP) er $23.01

Hva er markedsverdien på Harpoon Therapeutics, Inc. (HARP)

Markedsverdien på Harpoon Therapeutics, Inc. (HARP) er $74.80M

Harpoon Therapeutics, Inc. (HARP) Prishistorikk

Harpoon Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to immunotherapy, focused on engineering a novel class of T cell activators. These therapies are designed to leverage the body's own immune system to fight cancer and other diseases in patients across the United States. The company's innovative Tri-specific T cell activating construct (TriTAC) platform forms the basis of its development pipeline. This includes HPN328, currently undergoing Phase I/II clinical trials for small cell lung cancer and tumors that express Delta-like canonical Notch ligand 3; HPN217, also in Phase I/II trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical evaluation for ovarian and pancreatic cancers, alongside other mesothelin-expressing tumors. Furthermore, Harpoon has a preclinical asset, HPN601, aimed at various solid tumor indications. The company has also established a discovery collaboration and licensing agreement with AbbVie Biotechnology Ltd. to develop and market products combining its unique TriTAC technology with soluble T cell receptors. Founded in 2015, Harpoon Therapeutics, Inc. is headquartered in South San Francisco, California.

År	Ytelse
2024	118.66%
2023	37.41%
2022	-88.70%
2021	-54.80%
2020	-14.80%
2019	0.00%

År

Ytelse

2024

118.66%

2023

37.41%

2022

-88.70%

2021

-54.80%

2020

-14.80%

2019

0.00%

Selskap	Aksjepris	Endring 1år%	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$547.71	38.62%	US
Argenx SE ARGX.US	$1.04K	58.06%	NL
Moderna, Inc. MRNA.US	$145.75	437.43%	US
CSL Limited CSL.AX	$118.70	-15.60%	AU
Lonza Group AG LONN.SW	$770.19	8.98%	CH

Selskap

Aksjepris

Endring 1år%

Land